文献速递消化系统肿瘤

血管生成素-2血浆水平的早期变化预测转移性结直肠癌患者从瑞戈非尼治疗中获益

Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2022-02-26

REGOLAND多队列研究在105例回顾性探索队列、100例前瞻性验证队列及93例FTD/TPI对照队列中评估血管生成素-2(Ang-2)等循环标志物对瑞戈非尼疗效的预测价值。瑞戈非尼探索队列中,第15天Ang-2早期升高与更长的无进展生存相关(HR 0.57,95%CI 0.38-0.88,P=0.004),验证队列结果相似但未达统计学显著。FTD/TPI队列中Ang-2早期变化无预测作用;基线Ang-2高水平在所有队列中均独立预测不良预后。

要点

  • 瑞戈非尼探索队列中,第15天Ang-2升高者无进展生存优于降低者(HR 0.57,95%CI 0.38-0.88,P=0.004)。
  • 瑞戈非尼验证队列中,Ang-2早期变化对无进展生存的HR为0.72(95%CI 0.48-1.08,P=0.095)。
  • FTD/TPI队列中Ang-2早期变化无预测作用;基线Ang-2高水平在所有队列中独立预测不良预后。

核心结论

  • 循环Ang-2的早期变化可预测瑞戈非尼的疗效,基线Ang-2血浆水平是化疗难治性转移性结直肠癌的独立预后生物标志物。

研究设计与样本

  • 多队列REGOLAND研究:回顾性瑞戈非尼探索队列纳入105例接受瑞戈非尼治疗的患者,检测基线(d1)及治疗15天(d15)后血管生成相关标志物血浆水平与临床结局的相关性。
  • 前瞻性瑞戈非尼验证队列纳入100例接受瑞戈非尼治疗的患者,对探索队列的主要回顾性发现进行前瞻性验证。
  • 对照FTD/TPI队列纳入93例接受FTD/TPI治疗的患者,评估前瞻性验证的候选生物标志物。

主要发现

  • 瑞戈非尼探索队列中,第15天Ang-2升高(较基线)与更长的无进展生存相关(HR 0.57,95%CI 0.38-0.88,P=0.004),总生存有延长趋势(HR 0.74,95%CI 0.48-1.14,P=0.165)。
  • 瑞戈非尼验证队列中,第15天Ang-2升高与无进展生存的HR为0.72(95%CI 0.48-1.08,P=0.095),与总生存的HR为0.77(95%CI 0.51-1.16,P=0.204)。
  • FTD/TPI队列中,Ang-2的早期变化未显示预测作用。
  • 在所有研究队列中,基线Ang-2高水平独立于其他临床预后变量预测不良预后。

关键数值与推荐

  • 瑞戈非尼探索队列:第15天Ang-2升高者较降低者无进展生存HR 0.57(95%CI 0.38-0.88,P=0.004),总生存HR 0.74(95%CI 0.48-1.14,P=0.165)。
  • 瑞戈非尼验证队列:第15天Ang-2升高者较降低者无进展生存HR 0.72(95%CI 0.48-1.08,P=0.095),总生存HR 0.77(95%CI 0.51-1.16,P=0.204)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No biomarkers are currently available to predict the efficacy of trifluridine/tipiracil (FTD/TPI) in chemorefractory metastatic colorectal cancer. The multicohort REGOLAND study aims at exploring and validating circulating markers potentially able to predict benefit from regorafenib in this setting. MATERIAL AND METHODS: In the retrospective 'regorafenib exploratory cohort', including 105 patients treated with regorafenib, baseline (d1) plasma levels of angiogenesis-related biomarkers and their early modulation after 15 days (d15) of treatment were investigated for correlation with clinical outcome. Based on a pre-specified statistical hypothesis, main retrospective findings were prospectively challenged in the 'regorafenib validation cohort', including 100 patients treated with regorafenib. Prospectively validated putative biomarkers were then assessed in the control 'FTD/TPI cohort', including 93 patients treated with FTD/TPI. RESULTS: In the 'regorafenib exploratory cohort', the early (d15) increase of Angiopoietin-2 (Ang-2) was associated with longer progression-free survival (HR:0.57 [95%CI:0.38-0.88], P = 0.004) and a trend towards longer OS (HR:0.74 [95%CI:0.48-1.14], P = 0.165), than the early decrease. Similar results were prospectively confirmed in the 'regorafenib validation cohort' (HR for progression-free survival:0.72 [95%CI:0.48-1.08], P = 0.095; HR for OS:0.77 [95%CI:0.51-1.16], P = 0.204). No predictive impact was shown for the early modulation of Ang-2 in the 'FTD/TPI cohort'. High baseline Ang-2 levels predict poor prognosis in all the investigated cohorts, independently of other clinical prognostic variables. CONCLUSIONS: The early modulation of circulating Ang-2 predicts the efficacy of regorafenib. Baseline Ang-2 plasma levels are an independent prognostic biomarker in chemorefractory metastatic colorectal cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Antoniotti C, Marmorino F, Boccaccino A, et al. Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. Eur J Cancer. 2022. PMID: 35231767. doi:10.1016/j.ejca.2022.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。